Cargando…
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
OBJECTIVE: To evaluate the effect of ixekizumab on self‐reported functioning and health in patients with active nonradiographic axial spondyloarthritis (SpA). METHODS: COAST‐X was a randomized, controlled trial conducted in patients with nonradiographic axial SpA over 52 weeks. Participants were ran...
Autores principales: | Walsh, Jessica A., Magrey, Marina N., Baraliakos, Xenofon, Inui, Kentaro, Weng, Meng‐Yu, Lubrano, Ennio, van der Heijde, Désirée, Boonen, Annelies, Gensler, Lianne S., Strand, Vibeke, Braun, Jürgen, Hunter, Theresa, Li, Xiaoqi, Zhu, Baojin, León, Luis, Calderon, David Marcelino Sandoval, Kiltz, Uta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306696/ https://www.ncbi.nlm.nih.gov/pubmed/33044756 http://dx.doi.org/10.1002/acr.24482 |
Ejemplares similares
-
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020) -
A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019) -
Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
por: van der Heijde, Désirée, et al.
Publicado: (2014) -
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022) -
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)